Goldman Sachs
CATX icon

Goldman Sachs’s Perspective Therapeutics CATX Stock Holding History

Goldman Sachs’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.18M Buy
1,241,816
+1,081,979
+677% +$4.57M ﹤0.01% 3659
2025
Q4 		$440K Sell
159,837
-37,873
-19% -$108K ﹤0.01% 5671
2025
Q3 		$678K Sell
197,710
-74,388
-27% -$271K ﹤0.01% 5318
2025
Q2 		$936K Sell
272,098
-30,721
-10% -$81.1K ﹤0.01% 4762
2025
Q1 		$645K Sell
302,819
-600,099
-66% -$1.8M ﹤0.01% 5025
2024
Q4 		$2.88M Buy
902,918
+454,235
+101% +$3.71M ﹤0.01% 3983
2024
Q3 		$5.99M Buy
+448,683
New +$5.97M ﹤0.01% 3185
2024
Q2 		– Sell
-199,651
Closed -$2.38M – 5671
2024
Q1 		$2.38M Buy
+199,651
New +$1.7M ﹤0.01% 3748
2023
Q4 		– Sell
-1,337
Closed -$3.66K – 5640
2023
Q3 		$3.66K Buy
+1,337
New +$6.24K ﹤0.01% 5455
2016
Q1 		– Sell
-1,121
Closed -$11K – 7093
2015
Q4 		$11K Buy
+1,121
New +$14K ﹤0.01% 6956
2015
Q1 		– Sell
-1,101
Closed -$16K – 7091
2014
Q4 		$16K Sell
1,101
-6,557
-86% -$104K ﹤0.01% 7007
2014
Q3 		$129K Buy
7,658
+4,064
+113% +$101K ﹤0.01% 6452
2014
Q2 		$112K Buy
+3,594
New +$90.1K ﹤0.01% 6508

Other funds holding CATX

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs's CATX Position: Q1 2026 in Review

Goldman Sachs increased its Perspective Therapeutics (CATX) stake by 677% in Q1 2026, buying an estimated $4.57M and bringing the position to 1,241,816 shares worth $5.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3659.

Goldman Sachs first reported a position in CATX in Q2 2014 and has held it in 13 quarters since. The position peaked at $5.99M in Q3 2024. 138 funds tracked by Wall St. Rank hold CATX as of Q1 2026.

  • Goldman Sachs held 1,241,816 shares of Perspective Therapeutics worth $5.18M as of Q1 2026.
  • Goldman Sachs bought 1,081,979 Perspective Therapeutics shares in Q1 2026, an estimated $4.57M.
  • Perspective Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3659 holding.
  • Goldman Sachs first reported a position in Perspective Therapeutics in Q2 2014 and has held it in 13 quarters since.
  • Goldman Sachs's Perspective Therapeutics position peaked at $5.99M in Q3 2024.
  • 138 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.